1905935-4
IPOS's copy

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 211/58, A61K 31/445 — A1

(11) International Publication Number: WO 99/02496

(43) International Publication Date: 21 January 1999 (21.01.99)

(21) International Application Number: PCT/EP98/04193

(22) International Filing Date: 7 July 1998 (07.07.98)

(30) Priority Data:

97202161.2	11 July 1997 (11.07.97)	EP
98200661.1	4 March 1998 (04.03.98)	EP

(71) Applicant: JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B–2340 Beerse (BE).

(72) Inventors: HEYKANTS, Jozef, Jan, Pieter; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B–2340 Beerse (BE). MEGENS, Antonius, Adrianus, Hendrikus, Petrus; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B–2340 Beerse (BE). MEULDERMANS, Willem, Emiel, Gustaaf; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B–2340 Beerse (BE). SCHUURKES, Joannes, Adrianus, Jacobus; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B–2340 Beerse (BE).

(74) Agent: QUAGHEBEUR, Luc; Janssen Pharmaceutica N.V., Patent Dept., Turnhoutseweg 30, B–2340 Beerse (BE).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published


With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: (+)–NORCISAPRIDE USEFUL FOR 5–HT3 AND 5–HT4 MEDIATED DISORDERS


(57) Abstract

The present invention concerns (+)–norcisapride of formula (I) and compounds (V), and its pharmaceutically acceptable acid additions salts, a process for preparing said compound, and its use for the manufacture of a medicament for treating gastro–intestinal disorders while avoiding central nervous system effects. Also provided are method of treating gastro–intestinal disorders. Compounds of formula (V) wherein the piperidine ring has the absolute configuration (3S, 4R) and PG is methyloxycarbonyl, ethyloxycarbonyl, *tert*–butyloxycarbonyl or phenylmethyl.



(I)

(cis)



(V)